Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma

Allen, P. B., Lu, X., Chen, Q., O’Shea, K., Chmiel, J. S., Slonim, L. B., Sukhanova, M., Savas, H., Evens, A. M., Advani, R., Pro, B., Karmali, R., Palmer, B., Bayer, R. A., Eisner, R. M., Mou, E., Dillehay, G., Gordon, L. I., & Winter, J. N. (2023). Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Advances, 7(12), 2670–2676. https://doi.org/10.1182/bloodadvances.2022008116
Authors:
Pamela B. Allen
Xinyan Lu
Qing Chen
Kaitlyn O’Shea
Joan S. Chmiel
Yael Mozer‐Glassberg
Madina Sukhanova
Hatice Savas
Andrew M. Evens
Ranjana H. Advani
Barbara Pro
Reem Karmali
Brett Alan Palmer
Robert Bayer
Robert Eisner
Eric Mou
Gary Dillehay
Leo I. Gordon
Jane N. Winter
Affiliated Authors:
Barbara Pro
Columbia Affiliation:
Subjects:
Hodgkin Disease (MeSH)
Lymphoid Neoplasms (OpenAlex Topic)
Cancer Immunotherapy (OpenAlex Topic)
Diagnosis and Treatment of Primary Central Nervous System Lymphoma (OpenAlex Topic)
elink
Publication Type:
Article
Unique ID:
10.1182/bloodadvances.2022008116
PMID:
36083129
DOI:
10.1182/bloodadvances.2022008116
Journal:
Blood Advances
Publication Date:
Data Source:
OpenAlex
Source Link:
View OpenAlex Record
View PubMed Record
View Scopus Record

Record Created: